The Discount That Isn't: How Pharmaceutical Copay Assistance Programs Inflate Drug Prices and Raise Your Insurance Premiums

At first encounter, the logic of a pharmaceutical manufacturer's copay assistance card is intuitive and appealing. A brand-name medication carries a retail price of $400 per month. Your insurance plan requires a $75 copay. The manufacturer offers a savings card that reduces your out-of-pocket cost to $10. You pay less, you stay on the medication, and the transaction appears to benefit everyone involved.

The appearance, however, is precisely the point. What looks like patient-centered generosity is, in most cases, a carefully engineered business strategy—one that sustains artificially elevated drug list prices, keeps patients from switching to lower-cost generics, and disperses the resulting costs throughout the healthcare system in ways that are difficult to trace but very real in their consequences.

How Copay Assistance Actually Works

To understand why these programs exist, it helps to understand who pays for them and what they accomplish beyond the transaction you see at the pharmacy counter.

When a manufacturer offers a copay card, it is effectively covering the gap between what your insurer requires you to pay and a reduced amount the manufacturer has chosen to subsidize. The full list price of the drug—often hundreds or thousands of dollars per month—is still transmitted to the insurer and, by extension, to the pharmacy benefit manager (PBM) adjudicating the claim. The patient's financial burden is reduced. The drug's stated price is not.

This matters for a fundamental reason: insurers use drug pricing data, including list prices and total claim costs, to calculate the actuarial risk of their member populations. When expensive brand-name drugs are dispensed at high volume—even when patients are paying artificially low copays—the aggregate cost absorbed by the insurer remains elevated. Those costs are eventually recovered through premium adjustments, formulary restructuring, and benefit design changes that affect all enrollees.

In other words, the savings you experience at the pharmacy counter today may be partially contributing to the premium increase you receive in the mail next fall.

The Generic Barrier Built Into the System

One of the most consequential—and least-discussed—functions of manufacturer copay assistance is its role in suppressing generic drug utilization. When a lower-cost generic version of a medication becomes available, it typically enters the market at a fraction of the brand-name price, and insurers have strong financial incentives to steer patients toward it.

Manufacturers of brand-name drugs, anticipating this competitive pressure, often deploy copay assistance programs specifically to neutralize the cost advantage of the generic. If a brand-name medication costs a patient only $10 per month with a savings card, while the generic costs $15 under standard insurance terms, many patients will rationally remain on the brand. The manufacturer retains market share, the list price stays intact, and the insurer continues absorbing the full claim cost of the more expensive product.

Some insurers have responded with what are called "copay accumulator" and "copay maximizer" programs, which prevent manufacturer assistance from counting toward a patient's annual deductible or out-of-pocket maximum. These countermeasures are intended to restore the financial incentive for patients to choose generics or lower-tier formulary drugs. They have also generated significant controversy, particularly when patients are unaware of them and face unexpected cost exposure after their manufacturer assistance is exhausted.

The Price Inflation Incentive

The relationship between copay assistance and list prices is not coincidental—it is structural. Manufacturers have a diminished incentive to moderate list prices when they can simultaneously offer assistance programs that shield patients from experiencing those prices directly. The list price functions as the anchor for insurer negotiations, Medicaid rebate calculations, and international reference pricing benchmarks. Keeping it high serves multiple corporate interests, even when the actual transaction price is discounted.

Health economists have documented this dynamic in peer-reviewed research. A 2019 analysis published in the American Journal of Managed Care found that copay assistance programs were associated with higher net prices for brand-name drugs—not lower ones—because they reduced the competitive pressure that would otherwise encourage manufacturers to negotiate more aggressively with payers.

The result is a market in which the sticker price of a medication bears increasingly little relationship to what any single party actually pays, while the aggregate system cost continues to rise.

What Transparent Pricing Would Require

The gap between list price and net price—the price after all rebates, discounts, and assistance payments are accounted for—has become one of the pharmaceutical industry's most consequential points of opacity. Meaningful reform would require, at minimum, that manufacturers disclose net pricing publicly, that copay assistance be structured in ways that do not insulate list prices from market pressure, and that patients be clearly informed about how their assistance programs interact with their deductible accumulation.

Several legislative proposals at the federal level have sought to address elements of this problem. The Inflation Reduction Act of 2022 introduced Medicare drug price negotiation provisions and placed new constraints on price increases for certain drugs. But the broader commercial insurance market—where most working-age Americans receive coverage—remains largely outside these reforms.

Some states have passed or proposed legislation requiring greater price transparency from manufacturers. These efforts represent meaningful steps, but enforcement mechanisms and the complexity of pharmaceutical supply chain accounting have limited their practical impact.

What Patients Can Do With This Knowledge

None of this means that patients who qualify for copay assistance should refuse it. For individuals who are uninsured or who face significant financial hardship, manufacturer programs may represent the difference between affording a necessary medication and going without. That is a legitimate and important function.

But patients who have access to generic alternatives—and who are using brand-name copay cards primarily because the immediate out-of-pocket cost has been made artificially attractive—may benefit from a broader conversation with their pharmacist or prescribing physician. Questions worth asking include:

• Is there a therapeutically equivalent generic available for this medication?
• How does my insurer's copay accumulator policy affect whether this manufacturer assistance counts toward my deductible?
• Am I on this brand-name drug because it is clinically superior for my condition, or primarily because the copay card made it seem like the affordable choice?

The pharmaceutical pricing system in the United States is built on layers of incentives that are rarely visible to the individual patient. Copay assistance programs are among the most elegantly constructed of those layers—presenting themselves as patient advocacy while functioning, in significant part, as a mechanism for sustaining prices that the market would otherwise discipline. Recognizing that distinction is not a reason for cynicism. It is a basis for more informed decision-making.